CLRB - Positive Topline Pivotal Clinical Study Data could Propel this Biotech Listing

2024-01-08 06:56:58 ET

DENVER, Colo., Jan. 8, 2023 ( www.247marketnews.com )- Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported, this morning, data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia (WM) patients that have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitors (BTKi). CLOVER WaM is the largest study to date in relapsed or refractory WM patients post-BTKi therapy and represents the most refractory population ever tested in clinical studies based upon a review of published literature.

Cellectar Biosciences is trading at $3.00, up $0.29 (+10.70%), on 301K shares traded.

Its 52-week range is $ 1.30 to $3.20. This has a pretty decent chart and …

The post Positive Topline Pivotal Clinical Study Data could Propel this Biotech Listing appeared first on 24/7 Market News .

For further details see: